Drug Combo Granted Priority Review for Untreated Follicular Lymphoma

Leggi l'articolo originale


The FDA has granted Priority Review to Celgene’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma.

Lascia un commento